BERKELEY HEIGHTS, N.J., May 11, 2020 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the.

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, will host a call with Key Opinion Leaders (KOLs) on the potential of Neutrolin® for addressing antimicrobial resistance and catheter-related bloodstream infections (CRBSIs) on Tuesday, May 19th at 12pm Eastern Time. The call will feature presentations by KOLs Bruce Polsky, MD, MACP, FIDUSA (NYU Long Island School of Medicine and NYU Winthrop Hospital), Bruce Reidenberg, MD, FAAP, FCP (Weill Cornell Medicine), and Nelson P. Kopyt, DO (Lehigh Valley Health Network) who will discuss antimicrobial resistance, the current CRBSI landscape in patients with hemodialysis catheters, and Neutrolin®'s potential for preventing CRBSIs in these patients.

Today is shaping up negative for CorMedix Inc. (NYSEMKT:CRMD) shareholders, with the analysts delivering a substantial...

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the first quarter ended March 31, 2020, after the market close on Monday, May 11, and will host a corporate update conference call at 4:30pm Eastern Time. CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.

Top Ranked Momentum Stocks to Buy for April 22nd

As of late, it has definitely been a great time to be an investor CorMedix

Khoso Baluch became the CEO of CorMedix, Inc. (NYSEMKT:CRMD) in 2016. This analysis aims first to contrast CEO...

CorMedix (CRMD) delivered earnings and revenue surprises of 8.70% and -48.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has completed the previously announced sale of $5.5 million of the total $6.0 million of its available tax benefits to an unrelated, profitable New Jersey corporation through the New Jersey Economic Development Authority’s New Jersey Technology Business Tax Certificate Transfer program for State Fiscal Year 2019. As a result, the Company has received approximately $5.2 million in cash from the sale of these NOL tax benefits. “This transaction closed amid significant market volatility, so the timing could not be better,” commented Khoso Baluch, CorMedix CEO.

NEW YORK, NY / ACCESSWIRE / March 16, 2020 / CorMedix, Inc. (AMEX:CRMD) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 16, 2020 at 4:30 PM Eastern ...

Company in process of submitting New Drug Application (NDA) for Neutrolin® for prevention of catheter-related blood stream infections via a rolling review granted by FDA.

Editas Medicine (EDIT) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

CorMedix (CRMD) delivered earnings and revenue surprises of 12.50% and -73.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Q4 2019 CorMedix Inc Earnings Call

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

CorMedix Inc. (NYSE American:  CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has appointed Matt David, M.D. as the Company’s Executive Vice President and Chief Financial Officer. Dr. David will participate in the Company’s Conference Call discussing its First Quarter 2020 financial results and recent corporate developments today at 4:30pm Eastern time. “I am pleased that Matt has agreed to join the Company at this most exciting time,” said Khoso Baluch, CorMedix Chief Executive Officer.

CorMedix (CRMD) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has entered into a new three-year Employment Agreement with Jack Armstrong, currently Executive Vice President and Head of Technical Operations. The Employment Agreement was concluded as CorMedix works to secure marketing authorization for Neutrolin® in the second half of 2020 with potential commercial launch in the U.S. in 2021.

BERKELEY HEIGHTS, N.J., March 06, 2020 -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for.

CorMedix, Inc. (NYSEMKT:CRMD) missed earnings with its latest yearly results, disappointing overly-optimistic...